Attention Deficit Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Attention Deficit stocks.

Attention Deficit Stocks Recent News

Date Stock Title
May 2 ALKS Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
May 2 COLL Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
May 2 ALKS Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
May 1 ALKS Alkermes plc (ALKS) Q1 2024 Earnings Call Transcript
May 1 ALKS Alkermes plc 2024 Q1 - Results - Earnings Call Presentation
May 1 ITCI Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
May 1 ALKS Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say
May 1 ALKS Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
May 1 SUPN Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
May 1 ALKS Alkermes Non-GAAP EPS of $0.43 misses by $0.15, revenue of $350.4M misses by $9.87M
May 1 ALKS Alkermes plc Reports First Quarter 2024 Financial Results
Apr 30 ALKS Alkermes Q1 2024 Earnings Preview
Apr 30 ALKS How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits?
Apr 30 ITCI Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
Apr 30 DRRX DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
Apr 30 ITCI Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy
Apr 29 COLL Collegium enters authorized generic agreement with Hikma for Nucynta franchise
Apr 29 COLL Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
Apr 29 COLL Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
Attention Deficit

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, or excessive activity and impulsivity, which are otherwise not appropriate for a person's age. Some individuals with ADHD also display difficulty regulating emotions or problems with executive function. For a diagnosis, the symptoms should appear before a person is twelve years old, be present for more than six months, and cause problems in at least two settings (such as school, home, or recreational activities). In children, problems paying attention may result in poor school performance. Additionally, there is an association with other mental disorders and substance misuse. Although it causes impairment, particularly in modern society, many people with ADHD can have sustained attention for tasks they find interesting or rewarding (known as hyperfocus).Despite being the most commonly studied and diagnosed mental disorder in children and adolescents, the precise cause or causes are unknown in the majority of cases. Genetic factors are estimated to make up about 75% of the risk. Nicotine exposure during pregnancy may be an environmental risk. It does not appear to be related to the style of parenting or discipline. It affects about 5–7% of children when diagnosed via the DSM-IV criteria and 1–2% when diagnosed via the ICD-10 criteria. As of 2015, it was estimated to affect about 51.1 million people globally. Rates are similar between countries and depend mostly on how it is diagnosed. ADHD is diagnosed approximately two times more often in boys than in girls, although the disorder is often overlooked in girls because their symptoms can differ from those of boys. About 30–50% of people diagnosed in childhood continue to have symptoms into adulthood and between 2–5% of adults have the condition. In adults, inner restlessness, rather than hyperactivity, may occur. They often develop coping skills which make up for some or all of their impairments. The condition can be difficult to tell apart from other conditions, as well as to distinguish from high levels of activity that are still within the range of normal behaviors.ADHD management recommendations vary by country and usually involve some combination of counseling, lifestyle changes, and medications. The British guideline only recommends medications as a first-line treatment in children who have severe symptoms and for medication to be considered in those with moderate symptoms who either refuse or fail to improve with counseling, though for adults medications are a first-line treatment. Canadian and American guidelines recommend behavioral management as a first line treatment in preschool-aged children, while medications and behavioral therapy together are recommended after that. For children and adolescents, treatment with stimulants is effective for at least 14 months; however, their long-term effectiveness is unclear and there are potentially serious side effects.The medical literature has described symptoms similar to those of ADHD since the 18th century. ADHD, its diagnosis, and its treatment have been considered controversial since the 1970s. The controversies have involved clinicians, teachers, policymakers, parents, and the media. Topics include ADHD's causes and the use of stimulant medications in its treatment. Most healthcare providers accept ADHD as a genuine disorder in children and adults, and the debate in the scientific community mainly centers on how it is diagnosed and treated. The condition was officially known as attention deficit disorder (ADD) from 1980 to 1987, while before this it was known as hyperkinetic reaction of childhood.

Browse All Tags